DK0824918T3 - Behandling og forebyggelse af sygdomme forårsaget af NF-kappa B - Google Patents

Behandling og forebyggelse af sygdomme forårsaget af NF-kappa B

Info

Publication number
DK0824918T3
DK0824918T3 DK96913716T DK96913716T DK0824918T3 DK 0824918 T3 DK0824918 T3 DK 0824918T3 DK 96913716 T DK96913716 T DK 96913716T DK 96913716 T DK96913716 T DK 96913716T DK 0824918 T3 DK0824918 T3 DK 0824918T3
Authority
DK
Denmark
Prior art keywords
kappa
prevention
treatment
diseases caused
diseases
Prior art date
Application number
DK96913716T
Other languages
English (en)
Inventor
Ryuichi Morishita
Toshio Ogihara
Toshiko Sugimoto
Kazuhiro Maeda
Ikuo Kawamura
Toshiyuki Chiba
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of DK0824918T3 publication Critical patent/DK0824918T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK96913716T 1995-05-12 1996-05-10 Behandling og forebyggelse af sygdomme forårsaget af NF-kappa B DK0824918T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11499095 1995-05-12
JP28550495 1995-11-02
PCT/JP1996/001234 WO1996035430A1 (fr) 1995-05-12 1996-05-10 TRAITEMENT ET PREVENTION DE MALADIES ASSOCIEES A NF-λB

Publications (1)

Publication Number Publication Date
DK0824918T3 true DK0824918T3 (da) 2007-06-04

Family

ID=26453615

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96913716T DK0824918T3 (da) 1995-05-12 1996-05-10 Behandling og forebyggelse af sygdomme forårsaget af NF-kappa B

Country Status (9)

Country Link
US (4) US6262033B1 (da)
EP (1) EP0824918B1 (da)
JP (1) JP3474879B2 (da)
AT (1) ATE357922T1 (da)
DE (1) DE69636997T2 (da)
DK (1) DK0824918T3 (da)
ES (1) ES2285712T3 (da)
PT (1) PT824918E (da)
WO (1) WO1996035430A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0732929B1 (en) * 1993-10-29 2008-05-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
DK0824918T3 (da) * 1995-05-12 2007-06-04 Anges Mg Inc Behandling og forebyggelse af sygdomme forårsaget af NF-kappa B
IL131410A0 (en) 1997-02-15 2001-01-28 Proscript Inc Pharmaceutical compositions for treating infarcts through inhibition of nf-kappab
US6586661B1 (en) * 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
JP4215219B2 (ja) * 1997-07-04 2009-01-28 アンジェスＭｇ株式会社 脳保護剤
WO2000005234A1 (fr) * 1998-07-22 2000-02-03 Suntory Limited INHIBITEURS DE NF-λB CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
US7002003B1 (en) 1998-07-30 2006-02-21 University Of South Florida Method for the inhibition of function of STAT transcription factors
DE19926216A1 (de) * 1999-06-09 2001-02-22 Metallgesellschaft Ag Verfahren zur Herstellung von Bariumsulfat, Bariumsulfat und Verwendung des Bariumsulfats
CN1212861C (zh) * 1999-09-17 2005-08-03 第一三得利制药株式会社 以NF－κB抑制剂为有效成分的心肌炎、扩张型心肌病和心衰的预防或治疗药
JP2004507250A (ja) * 2000-08-30 2004-03-11 ノース・キャロライナ・ステイト・ユニヴァーシティ タンパク質含量を変化させる分子デコイを含有するトランスジェニック植物
JP2002065278A (ja) * 2000-08-31 2002-03-05 Anges Mg Inc Ｈｖｊの融合タンパク質を含有する遺伝子移入ビヒクル
WO2002038588A2 (en) * 2000-11-07 2002-05-16 North Carolina State University Putrescine-n-methyltransferase promoter
AU2002258399A1 (en) * 2001-02-16 2002-09-19 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
US9012417B2 (en) * 2001-02-20 2015-04-21 Anges Mg, Inc. Topical administration of NF-kappaB decoy to treat atopic dermatitis
EP1406518A4 (en) * 2001-06-08 2006-03-29 Vector Tobacco Ltd CHANGES IN NICOTINE AND NITROSAMINE LEVELS IN TOBACCO
US20060157072A1 (en) * 2001-06-08 2006-07-20 Anthony Albino Method of reducing the harmful effects of orally or transdermally delivered nicotine
CA2467915A1 (en) * 2001-11-22 2003-05-30 Anges Mg, Inc. Compositions inhibiting rejection in organ transplantation and method of using the same
DE60231063D1 (de) 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
WO2003082331A1 (fr) * 2002-03-29 2003-10-09 Anges Mg, Inc. Compositions de leurre destinees au traitement et a la prevention de maladies et de pathologies cerebrales
CN100337542C (zh) * 2002-04-09 2007-09-19 韦克多烟草有限公司 低尼古丁和亚硝胺的烟草
EP1499721B1 (en) 2002-04-26 2013-05-29 AnGes MG, Inc. CIRCULAR DUMBBELL DECOY OLIGODEOXYNUCLEOTIDES (CDODN) CONTAINING DNA BINDINGS SITES FOR THE TRANSCRIPTION FACTOR NF-kappa B
EP1512415A4 (en) * 2002-05-29 2005-11-09 Anges Mg Inc LURE COMPOSITION FOR TREATING AND PREVENTING INFLAMMATORY DISEASES
CN1674881A (zh) * 2002-06-26 2005-09-28 学校法人庆应义塾 含NF－κB抑制剂的医药组合物
US20060233815A1 (en) * 2002-09-20 2006-10-19 Anges Mg. Inc Agents for protection from neointimal formation in grafts comprising an nfkappab decoy
CN1784248B (zh) * 2003-05-09 2010-11-10 森下龙一 收容药剂的无针注射器
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
US6884443B2 (en) 2003-08-07 2005-04-26 General Mills, Inc. Compositions and methods relating to freezer-to-oven doughs
EP1691817A2 (en) * 2003-12-02 2006-08-23 Corgentech, Inc. NF-kB OLIGONUCLEOTIDE DECOY MOLECULES
US7927873B2 (en) * 2003-12-19 2011-04-19 University Of Cincinnati Polyamides for nucleic acid delivery
SE0400399D0 (sv) * 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
US20060069055A1 (en) * 2004-09-21 2006-03-30 Maya Dajee Delivery of polynucleotides
ATE509100T1 (de) 2004-10-22 2011-05-15 Anges Mg Inc Chimäre (doppel-) attrappe
JPWO2006064886A1 (ja) * 2004-12-16 2008-06-12 アンジェスＭｇ株式会社 骨形成調節剤
US7585848B2 (en) 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20090215868A1 (en) * 2005-01-13 2009-08-27 Anges Mg, Inc. Therapeutic Medicament for Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, and Pulmonary Hypertension
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
CA2614295A1 (en) 2005-06-06 2006-12-14 Anges Mg, Inc. Transcription factor decoy
US20100167390A1 (en) * 2005-12-22 2010-07-01 Toshohiro Nakajima Novel Oligonucleotide and NF-kB Decoy Comprising the Same
US8501478B2 (en) * 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
EP2127681A4 (en) 2007-02-16 2011-10-12 Anges Mg Inc THERAPEUTIC AGENT AGAINST PARODONTAL DISEASES AND ALVEOLAR BONE LOSS THROUGH OPERATION
JP5312747B2 (ja) * 2007-03-01 2013-10-09 ジェノミディア株式会社 Ｈｖｊエンベロープによるタンパク質の導入方法
WO2008141308A2 (en) 2007-05-11 2008-11-20 Adynxx, Inc. Gene expression and pain
US20110092438A1 (en) * 2008-03-28 2011-04-21 Angesmg, Inc. Composition for external application comprising transcription factor decoy as active ingredient
JP5057587B2 (ja) * 2009-05-20 2012-10-24 アンジェスＭｇ株式会社 デコイを含む薬学的組成物およびその使用方法
AU2012295913A1 (en) 2011-08-12 2014-03-13 Tagcyx Biotechnologies Production method for nucleic acid aptamer
CN104487096B (zh) 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
RU2017108238A (ru) 2014-08-15 2018-09-17 Эйдинкс, Инк. Олигонуклеотиды-приманки для лечения боли
EP3366773A4 (en) * 2015-10-23 2019-06-12 Rena Therapeutics Inc. NUCLEIC ACID COMPLEX

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
AU2140592A (en) 1991-05-17 1992-12-30 Chiron Corporation Inhibitor of nf-kappa b transcriptional activator and uses thereof
CA2105595A1 (en) 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
EP0652290A1 (en) * 1993-09-07 1995-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for regulation of NF-kB
CA2131587A1 (en) 1993-09-07 1995-03-08 Yinon Ben-Neriah Method for regulation of nf-kb
JPH07114990A (ja) 1993-10-14 1995-05-02 Plus Kk ハロゲンランプ調光装置
EP0732929B1 (en) 1993-10-29 2008-05-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US6399376B1 (en) 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
JPH07285504A (ja) 1994-04-14 1995-10-31 Asano Seiki Kk 粉粒体充填装置
DK0824918T3 (da) 1995-05-12 2007-06-04 Anges Mg Inc Behandling og forebyggelse af sygdomme forårsaget af NF-kappa B

Also Published As

Publication number Publication date
PT824918E (pt) 2007-06-22
US20020098162A1 (en) 2002-07-25
EP0824918A4 (en) 2004-11-17
US20040162250A1 (en) 2004-08-19
US6262033B1 (en) 2001-07-17
WO1996035430A1 (fr) 1996-11-14
JP3474879B2 (ja) 2003-12-08
EP0824918A1 (en) 1998-02-25
US20060116344A1 (en) 2006-06-01
ES2285712T3 (es) 2007-11-16
ATE357922T1 (de) 2007-04-15
EP0824918B1 (en) 2007-03-28
DE69636997T2 (de) 2007-07-12
DE69636997D1 (de) 2007-05-10
US7871983B2 (en) 2011-01-18

Similar Documents

Publication Publication Date Title
DK0824918T3 (da) Behandling og forebyggelse af sygdomme forårsaget af NF-kappa B
DE69615510T2 (de) Passivierung von organischen Vorrichtungen
DE69630162D1 (de) Passivierung von organischen Vorrichtungen
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69213702D1 (de) Feldeffekttransistor
DE69613945T2 (de) Passivierung von organischen elektrolumineszenten Vorrichtungen
DE69325673T2 (de) Feldeffekttransistor
DE69206034D1 (de) Korrosionsschutz von FeMn mittels Ionenimplantierung.
FI973362A0 (fi) Transdermaalinen formula
DE29506778U1 (de) Stechmücken-Vernichtungsvorrichtung
ATE187867T1 (de) Insektenfalle zum schutz von vieh
DE69332112T2 (de) Verbesserter biolarer Transistor
DE69306260T2 (de) Behandlung von abwasser
KR920004507U (ko) 배수용 트랩
DE69318686D1 (de) Komplementärer Feldeffekt-Transistor
KR940010189U (ko) 배수구가 가변되는 배수트랩
KR950009066U (ko) 배수트랩
KR930011143U (ko) 경사면 보호 앙카 드레인 벨트
DE9309382U1 (de) Wühlmausfalle
DE69306136D1 (de) Transistorfolgeverstärker
KR950001378U (ko) 배수트랩
DK140793D0 (da) Vandlaas
KR970039430U (ko) 배수트랩
KR940024906U (ko) 배수 트랩
KR950019046U (ko) 배수용 트랩